Login to Your Account



Washington Roundup

Annual Biosimilar Fees Only A Stopgap: Industry to FDA

By Mari Serebrov
Washington Editor

Monday, December 19, 2011
WASHINGTON – An annual development fee may be necessary to get the biosimilar pathway up and running, but it should be considered a stopgap measure that will end once the route is established, industry representatives told the FDA.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription